Works by Rasco, Drew

Results: 23

The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research.
Published in:
Oncologist, 2009, v. 14, n. 5, p. 468, doi. 10.1634/theoncologist.2008-0268
By:
- RASCO, DREW W.;
- YANG XIE;
- JINGSHENG YAN;
- SAYNE, JENNIFER R.;
- SKINNER, CELETTE SUGG;
- DOWELL, JONATHAN E.;
- GERBER, DAVID E.
Publication type:
Article
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
Published in:
Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 329, doi. 10.1007/s00280-023-04613-9
By:
- Biesdorf, Carla;
- Guan, Xiaowen;
- Siddani, Satya R.;
- Hoffman, David;
- Boehm, Nils;
- Medeiros, Bruno C.;
- Doi, Toshihiko;
- de Jonge, Maja;
- Rasco, Drew;
- Menon, Rajeev M.;
- Polepally, Akshanth R.
Publication type:
Article
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 1, p. 15, doi. 10.1007/s00280-023-04544-5
By:
- Rasco, Drew W.;
- Medina, Theresa;
- Corrie, Pippa;
- Pavlick, Anna C.;
- Middleton, Mark R.;
- Lorigan, Paul;
- Hebert, Chris;
- Plummer, Ruth;
- Larkin, James;
- Agarwala, Sanjiv S.;
- Daud, Adil I.;
- Qiu, Jiaheng;
- Bozon, Viviana;
- Kneissl, Michelle;
- Barry, Elly;
- Olszanski, Anthony J.
Publication type:
Article
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Published in:
Oncology, 2019, v. 97, n. 2, p. 102, doi. 10.1159/000500571
By:
- Hong, David;
- Rasco, Drew;
- Veeder, Michael;
- Luke, Jason J.;
- Chandler, Jason;
- Balmanoukian, Ani;
- George, Thomas J.;
- Munster, Pamela;
- Berlin, Jordan D.;
- Gutierrez, Martin;
- Mita, Alain;
- Wakelee, Heather;
- Samakoglu, Selda;
- Guan, Shanhong;
- Dimery, Isaiah;
- Graef, Thorsten;
- Borazanci, Erkut
Publication type:
Article
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
Published in:
Journal of Clinical Pharmacology, 2018, v. 58, n. 2, p. 180, doi. 10.1002/jcph.988
By:
- Gupta, Neeraj;
- Hanley, Michael J.;
- Venkatakrishnan, Karthik;
- Bessudo, Alberto;
- Rasco, Drew W.;
- Sharma, Sunil;
- O'Neil, Bert H.;
- Wang, Bingxia;
- Liu, Guohui;
- Ke, Alice;
- Patel, Chirag;
- Rowland Yeo, Karen;
- Xia, Cindy;
- Zhang, Xiaoquan;
- Esseltine, Dixie‐Lee;
- Nemunaitis, John
Publication type:
Article
Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181).
Published in:
CTS: Clinical & Translational Science, 2021, v. 14, n. 1, p. 277, doi. 10.1111/cts.12855
By:
- Powderly, John;
- Spira, Alexander;
- Kondo, Shunsuke;
- Doi, Toshihiko;
- Luke, Jason J.;
- Rasco, Drew;
- Gao, Bo;
- Tanner, Minna;
- Cassier, Philippe A.;
- Gazzah, Anas;
- Italiano, Antoine;
- Tosi, Diego;
- Afar, Daniel E.;
- Parikh, Apurvasena;
- Engelhardt, Benjamin;
- Englert, Stefan;
- Lambert, Stacie L.;
- Kasichayanula, Sreeneeranj;
- Mensing, Sven;
- Menon, Rajeev
Publication type:
Article
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Published in:
2018
By:
- Goss, Glenwood D.;
- Vokes, Everett E.;
- Gordon, Michael S.;
- Gandhi, Leena;
- Papadopoulos, Kyriakos P.;
- Rasco, Drew W.;
- Fischer, JuDee S.;
- Chu, Katharine L.;
- Ames, William W.;
- Mittapalli, Rajendar K.;
- Lee, Ho‐Jin;
- Zeng, Jiewei;
- Roberts‐Rapp, Lisa A.;
- Loberg, Lise I.;
- Ansell, Peter J.;
- Reilly, Edward B.;
- Ocampo, Christopher J.;
- Holen, Kyle D.;
- Tolcher, Anthony W.;
- Lee, Ho-Jin
Publication type:
journal article
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
Published in:
Leukemia & Lymphoma, 2015, v. 56, n. 6, p. 1763, doi. 10.3109/10428194.2014.974040
By:
- Papadopoulos, Kyriakos P.;
- Egile, Coumaran;
- Ruiz-Soto, Rodrigo;
- Jiang, Jason;
- Shi, Weiliang;
- Bentzien, Frauke;
- Rasco, Drew;
- Abrisqueta, Pau;
- Vose, Julie M.;
- Tabernero, Josep
Publication type:
Article
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Published in:
Investigational New Drugs, 2024, v. 42, n. 3, p. 241, doi. 10.1007/s10637-024-01428-0
By:
- Chénard-Poirier, Maxime;
- Hansen, Aaron R.;
- Gutierrez, Martin E.;
- Rasco, Drew;
- Xing, Yan;
- Chen, Lin-Chi;
- Zhou, Heng;
- Webber, Andrea L.;
- Freshwater, Tomoko;
- Sharma, Manish R.
Publication type:
Article
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Published in:
Investigational New Drugs, 2022, v. 40, n. 4, p. 762, doi. 10.1007/s10637-022-01247-1
By:
- LoRusso, Patricia;
- Ratain, Mark J.;
- Doi, Toshihiko;
- Rasco, Drew W.;
- de Jonge, Maja J. A.;
- Moreno, Victor;
- Carneiro, Benedito A.;
- Devriese, Lot A.;
- Petrich, Adam;
- Modi, Dimple;
- Morgan-Lappe, Susan;
- Nuthalapati, Silpa;
- Motwani, Monica;
- Dunbar, Martin;
- Glasgow, Jaimee;
- Medeiros, Bruno C.;
- Calvo, Emiliano
Publication type:
Article
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Published in:
Investigational New Drugs, 2017, v. 35, n. 2, p. 189, doi. 10.1007/s10637-016-0409-9
By:
- Cleary, James;
- Rosen, Lee;
- Yoshida, Kenichiro;
- Rasco, Drew;
- Shapiro, Geoffrey;
- Sun, Weijing
Publication type:
Article
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.
Published in:
Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 93, doi. 10.1007/s00280-021-04358-3
By:
- Patnaik, Amita;
- Weiss, Glen J.;
- Rasco, Drew W.;
- Blaydorn, Lisa;
- Mirabella, Amy;
- Beeram, Murali;
- Guo, Wei;
- Lu, Sharon;
- Danaee, Hadi;
- McEachern, Kristen;
- Im, Ellie;
- Sachdev, Jasgit C.
Publication type:
Article
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Published in:
2018
By:
- Patnaik, Amita;
- Papadopoulos, Kyriakos P.;
- Rasco, Drew;
- Beeram, Muralidhar;
- Gordon, Michael;
- Tsai, Frank;
- Fu, Siqing;
- Janku, Filip;
- Hong, David;
- Hynes, Scott M.;
- Gundala, Sushma R.;
- Willard, Melinda D.;
- Zhang, Wei;
- Lin, Aimee Bence
Publication type:
journal article
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.
Published in:
2018
By:
- Patnaik, Amita;
- Papadopoulous, Kyri;
- Rasco, Drew;
- Beeram, S. Muralidhar;
- Gordon, Michael;
- Tsai, Frank;
- Fu, Siqing;
- Janku, Filip;
- Hong, David;
- Hynes, Scott M.;
- Gundala, Sushma R.;
- Willard, Melinda D.;
- Zhang, Wei;
- Lin, Aimee Bence;
- Papadopoulos, Kyriakos P;
- Beeram, Muralidhar
Publication type:
journal article
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Published in:
2016
By:
- Patnaik, Amita;
- Tolcher, Anthony;
- Papadopoulos, Kyriakos;
- Beeram, Murali;
- Rasco, Drew;
- Werner, Theresa;
- Bauman, John;
- Scheuber, Anita;
- Cox, Donna;
- Patel, Bela;
- Zhou, YanYan;
- Hamid, Mohammed;
- Schramek, Daniel;
- Sharma, Sunil;
- Papadopoulos, Kyriakos P;
- Werner, Theresa L;
- Bauman, John W;
- Cox, Donna S;
- Patel, Bela R
Publication type:
journal article
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
Published in:
2015
By:
- Papadopoulos, Kyriakos P;
- Isaacs, Randi;
- Bilic, Sanela;
- Kentsch, Kerstin;
- Huet, Heather A;
- Hofmann, Matthias;
- Rasco, Drew;
- Kundamal, Nicole;
- Tang, Zhongwhen;
- Cooksey, Jennifer;
- Mahipal, Amit
Publication type:
journal article
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor.
Published in:
Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 887, doi. 10.1007/s00280-015-2712-0
By:
- Papadopoulos, Kyriakos;
- Isaacs, Randi;
- Bilic, Sanela;
- Kentsch, Kerstin;
- Huet, Heather;
- Hofmann, Matthias;
- Rasco, Drew;
- Kundamal, Nicole;
- Tang, Zhongwhen;
- Cooksey, Jennifer;
- Mahipal, Amit
Publication type:
Article
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Published in:
Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 1, p. 183, doi. 10.1007/s00280-014-2615-5
By:
- Tolcher, Anthony;
- Patnaik, Amita;
- Papadopoulos, Kyriakos;
- Rasco, Drew;
- Becerra, Carlos;
- Allred, Alicia;
- Orford, Keith;
- Aktan, Gursel;
- Ferron-Brady, Geraldine;
- Ibrahim, Nageatte;
- Gauvin, Jennifer;
- Motwani, Monica;
- Cornfeld, Mark
Publication type:
Article
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
Published in:
Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 363, doi. 10.1007/s00280-013-2361-0
By:
- Tolcher, Anthony;
- Rodrigueza, Wendi;
- Rasco, Drew;
- Patnaik, Amita;
- Papadopoulos, Kyriakos;
- Amaya, Alex;
- Moore, Timothy;
- Gaylor, Shari;
- Bisgaier, Charles;
- Sooch, Mina;
- Woolliscroft, Michael;
- Messmann, Richard
Publication type:
Article
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Published in:
Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
By:
- Tolcher, Anthony;
- Flaherty, Keith;
- Shapiro, Geoffrey I.;
- Berlin, Jordan;
- Witzig, Thomas;
- Habermann, Thomas;
- Bullock, Andrea;
- Rock, Edwin;
- Elekes, Agnes;
- Lin, Chester;
- Kostic, Dusan;
- Ohi, Naoto;
- Rasco, Drew;
- Papadopoulos, Kyriakos P.;
- Patnaik, Amita;
- Smith, Lon;
- Cote, Gregory M.
Publication type:
Article
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Published in:
Cancers, 2022, v. 14, n. 20, p. 4996, doi. 10.3390/cancers14204996
By:
- Patnaik, Amita;
- Hamilton, Erika;
- Xing, Yan;
- Rasco, Drew W.;
- Smith, Lon;
- Lee, Ya-Li;
- Fang, Steven;
- Wei, Jiao;
- Hui, Ai-Min
Publication type:
Article
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Published in:
Targeted Oncology, 2022, v. 17, n. 2, p. 125, doi. 10.1007/s11523-022-00875-0
By:
- Patnaik, Amita;
- Gadgeel, Shirish;
- Papadopoulos, Kyriakos P.;
- Rasco, Drew W.;
- Haas, Naomi B.;
- Der-Torossian, Hirak;
- Faltaos, Demiana;
- Potvin, Diane;
- Tassell, Vanessa;
- Tawashi, Manal;
- Chao, Richard;
- O'Dwyer, Peter J.
Publication type:
Article
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Published in:
2022
By:
- Patnaik, Amita;
- Gadgeel, Shirish;
- Papadopoulos, Kyriakos P.;
- Rasco, Drew W.;
- Haas, Naomi B.;
- Der-Torossian, Hirak;
- Faltaos, Demiana;
- Potvin, Diane;
- Tassell, Vanessa;
- Tawashi, Manal;
- Chao, Richard;
- O'Dwyer, Peter J.
Publication type:
Correction Notice